<DOC>
	<DOCNO>NCT02534870</DOCNO>
	<brief_summary>The purpose study ass pharmacokinetics safety multiple oral dos ABT-450/ritonavir/ABT-267 ABT-333 co-administered non-fasting condition healthy Chinese adult participant .</brief_summary>
	<brief_title>Pharmacokinetics Safety Co-administration ABT-450/Ritonavir/ABT-267 ( ABT-450/r/ABT-267 ) ABT-333 Healthy Chinese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Participant must Chinese ( i.e. , Chinese ancestry ) . If female , participant must either postmenopausal least 2 year , surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) , practice least one follow method birth control male partner ( ) : total abstinence sexual intercourse preferred life style subject , periodic abstinence acceptable ; vasectomize partner ( ) ; hormonal contraceptive ( oral , parenteral transdermal ) least 3 month prior study drug administration ; intrauterine device ( IUD ) ; doublebarrier method ( condom , contraceptive sponge , diaphragm spermicidal jelly cream ) Hormonal contraceptive , include limited oral , topical , injectable implantable variety , may use study . If male , participant must surgically sterile practice least 1 follow method contraception , refrain sperm donation , initial study drug administration 90 day last dose study drug : partner ( ) use IUD ; partner ( ) use oral , injected , intravaginal , implanted method hormonal contraceptive ; participant and/or partner ( ) use doublebarrier method ( condom , contraceptive sponge , diaphragm spermicidal jelly cream , vaginal ring ) ; total abstinence sexual intercourse preferred life style subject ; periodic abstinence acceptable Body Mass Index ( BMI ) â‰¥ 18 &lt; 30 kg/m^2 . A condition general good health , base upon result medical history , physical examination , vital sign , laboratory profile , 12lead electrocardiogram ( ECG ) chest xray ( CXR ) . Use medication ( prescription overthecounter ) , vitamins and/or herbal supplement within 2week period prior first dose study drug administration within 10 halflives respective medication , whichever longer . History epilepsy , clinically significant cardiovascular , respiratory ( except mild asthma ) , renal , hepatic , gastrointestinal , hematologic , neurologic , thyroid , uncontrolled medical illness psychiatric disease disorder . Clinically significant abnormal ECG : ECG QT interval correct heart rate use Fridericia 's correction formula ( QTcF ) &gt; 450 msec female &gt; 430 msec male , ECG second third degree atrioventricular block . Previous exposure single dose ABT450/r/ABT267 , ABT333 within past 12 week , previous participation study . Consideration investigator , reason , subject unsuitable candidate receive ABT450 , ritonavir , ABT267 , ABT333 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Volunteer</keyword>
</DOC>